Amylyx drug helps slow ALS progression in mid-stage study

Privately held drug developer Amylyx Pharmaceuticals Inc said on Tuesday its experimental therapy to treat amyotrophic lateral sclerosis (ALS) helped slow the progression of the fatal neurological disorder in a mid-stage study.

Source: Reuters: Health - December 17, 2019 Category: Consumer Health News Tags: healthNews Source Type: news